Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment
| العنوان: | Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment |
|---|---|
| المؤلفون: | Katarzyna Piekarowicz, Volha Dzianisava, Magdalena Machowska, Ryszard Rzepecki |
| المصدر: | Cells, Vol 8, Iss 2, p 88 (2019) Cells |
| بيانات النشر: | MDPI AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | congenital, hereditary, and neonatal diseases and abnormalities, Laminopathy, miR9, Review, laminopathy, Biology, Bioinformatics, medicine.disease_cause, LMNA, Exon, Progeria, medicine, Animals, Humans, Genetic Predisposition to Disease, Gene, lcsh:QH301-705.5, lamin A/C, Mutation, integumentary system, nutritional and metabolic diseases, General Medicine, Genetic Therapy, medicine.disease, Progerin, gene therapy, Disease Models, Animal, Phenotype, lcsh:Biology (General), progerin, HGPS, Lamin |
| الوصف: | Hutchinson-Gilford progeria syndrome (HGPS) is one of the most severe disorders among laminopathies—a heterogeneous group of genetic diseases with a molecular background based on mutations in the LMNA gene and genes coding for interacting proteins. HGPS is characterized by the presence of aging-associated symptoms, including lack of subcutaneous fat, alopecia, swollen veins, growth retardation, age spots, joint contractures, osteoporosis, cardiovascular pathology, and death due to heart attacks and strokes in childhood. LMNA codes for two major, alternatively spliced transcripts, give rise to lamin A and lamin C proteins. Mutations in the LMNA gene alone, depending on the nature and location, may result in the expression of abnormal protein or loss of protein expression and cause at least 11 disease phenotypes, differing in severity and affected tissue. LMNA gene-related HGPS is caused by a single mutation in the LMNA gene in exon 11. The mutation c.1824C > T results in activation of the cryptic donor splice site, which leads to the synthesis of progerin protein lacking 50 amino acids. The accumulation of progerin is the reason for appearance of the phenotype. In this review, we discuss current knowledge on the molecular mechanisms underlying the development of HGPS and provide a critical analysis of current research trends in this field. We also discuss the mouse models available so far, the current status of treatment of the disease, and future prospects for the development of efficient therapies, including gene therapy for HGPS. |
| اللغة: | English |
| تدمد: | 2073-4409 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1c2aba3f250468fee31d74bb3d3199Test https://www.mdpi.com/2073-4409/8/2/88Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....de1c2aba3f250468fee31d74bb3d3199 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20734409 |
|---|